<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01759251</url>
  </required_header>
  <id_info>
    <org_study_id>P13-972</org_study_id>
    <nct_id>NCT01759251</nct_id>
  </id_info>
  <brief_title>Effectiveness of Betaserc® (Betahistine Dihydrochloride) in Patients With Vestibular Vertigo in Routine Practice</brief_title>
  <acronym>VIRTUOSO</acronym>
  <official_title>Post-marketing Observational Program of Betaserc® (Betahistine Dihydrochloride) to Evaluate Effectiveness in Patients With Vestibular Vertigo in Routine Practice</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abbott</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Abbott</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purposes of this international post-marketing observational program is to investigate
      effectiveness of betahistine dihydrochloride (Betaserc®) tablets and assess the course of
      vestibular vertigo after treatment discontinuation in population of Russia and Ukraine
      outpatients suffering from vestibular vertigo in pragmatic clinical settings. Exploratory
      analyses of results from both participating countries may be expected to provide insights
      about the subjective circumstances of vestibular vertigo patients in a wider than usual range
      of gender, underlying ICD-10 diagnosis, national and cultural situations.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A prospective, multicentre, non-interventional, non-randomized, non-controlled, single arm,
      post-marketing observational program in patients whom betahistine dihydrochloride (Betaserc®)
      tablets were prescribed in the usual manner at the maximal recommended daily dose of 48 mg in
      accordance with the locally approved label. Over a program period physician is free to adjust
      betahistine dihydrochloride dose according to country approved label. Adult outpatients with
      vestibular vertigo who can be treated with betahistine dihydrochloride as per the locally
      approved label will be enrolled in the program. The program consists of an observational
      treatment period (up to 2 months) and a follow-up period (up to 2 months, for evaluation of
      the course of vestibular vertigo after treatment completion).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Actual">May 2014</completion_date>
  <primary_completion_date type="Actual">May 2014</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Scale for Vestibular Vertigo Severity Level and Clinical Response Evaluation (SVVSLCRE)</measure>
    <time_frame>Up to 2 months</time_frame>
    <description>Number of patients with clinical response on treatment determined with SVVSLCRE</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change of the Patient's Clinical Conditions of Vestibular Vertigo From Baseline to the End of Observational Treatment Period</measure>
    <time_frame>From Day 0 to 2 months</time_frame>
    <description>determined with the Scale for Vestibular Vertigo Severity Level and Clinical Response Evaluation (SVVSLCRE)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of Vestibular Vertigo Attacks Frequency From Baseline to the End of Observational Treatment Period</measure>
    <time_frame>From Day 0 to 2 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of Vestibular Vertigo Attacks Frequency From the End of Observational Treatment Period to the End of Follow-up Period</measure>
    <time_frame>From 2 months to 4 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Clinical Response Assessed by Physician</measure>
    <time_frame>up to 2 months</time_frame>
    <description>determined with a four-point-scale, where 4 = excellent, 3 = good, 2 = fair, and 1 = poor.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Clinical Response Assessed by Patient</measure>
    <time_frame>up to 2 months</time_frame>
    <description>determined with a four-point-scale, where 4 = excellent, 3 = good, 2 = fair, and 1 = poor.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Response as Improvement of Vertigo Associated Symptoms Evaluated by Physician</measure>
    <time_frame>up to 2 months</time_frame>
    <description>vertigo associated symptoms: tinnitus, hearing loss, nausea, vomiting, faintness and headache; determined with a four-point-scale, where 4 = excellent, 3 = good, 2 = fair, and 1 = poor.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Response as Improvement of Vertigo Associated Symptoms Evaluated by Patient</measure>
    <time_frame>up to 2 months</time_frame>
    <description>vertigo associated symptoms: tinnitus, hearing loss, nausea, vomiting, faintness and headache; determined with a four-point-scale, where 4 = excellent, 3 = good, 2 = fair, and 1 = poor.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">309</enrollment>
  <condition>Vertigo</condition>
  <arm_group>
    <arm_group_label>vestibular vertigo</arm_group_label>
    <description>Patients with vestibular vertigo of known or unknown origin, and for whom the physician has decided to prescribe betahistine dihydrochloride at dose 48 mg/day in accordance with locally approved label</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        outpatients with vestibular vertigo
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria

          -  Male or female 18 years and older.

          -  Patients with vestibular vertigo of known or unknown origin, and for whom the
             physician has decided to prescribe 48 mg of betahistine dihydrochloride (Betaserc®) in
             accordance with locally approved label.

          -  Patients who are willing and able to provide authorization to the investigator to use
             and/or disclose personal and/or health data.

          -  Patients who started betahistine dihydrochloride (Betaserc®) therapy not more than 5
             days priory to sign Patient Authorization (Consent) for Use/Disclosure of Data.

        Exclusion Criteria

          -  Patients with any condition which, in the opinion of the Investigator, makes the
             patient unsuitable for inclusion based on clinical judgment.

          -  Labeled contraindications of betahistine dihydrochloride (Betaserc®) treatment.

          -  Patients with middle or inner ear infection.

          -  Patient with psychiatric disorders, significant neurological disorder or spinal cord
             damage.

          -  Patients receiving any other agents for peripheral vestibular vertigo such as
             diuretics, transtympanic gentamycin, cinnarizine, competitive antagonist of histamine,
             blocking H1- histamine receptors.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean-Pascal Berrou, MD</last_name>
    <role>Study Director</role>
    <affiliation>Abbott</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Site reference ID 89414</name>
      <address>
        <city>Belgorod</city>
        <zip>308007</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research facility ID ORG-000838</name>
      <address>
        <city>Irkutsk</city>
        <zip>664047</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site reference ID 89433</name>
      <address>
        <city>Kazan</city>
        <zip>420012</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site reference ID 89454</name>
      <address>
        <city>Moscow</city>
        <zip>119991</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site reference ID 89419</name>
      <address>
        <city>Moscow</city>
        <zip>123007</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research facility ID ORG-000837</name>
      <address>
        <city>Moscow</city>
        <zip>125047</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site reference ID 94374</name>
      <address>
        <city>Moscow</city>
        <zip>127006</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site reference ID 89416</name>
      <address>
        <city>Moscow</city>
        <zip>129110</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site reference ID 89435</name>
      <address>
        <city>Novosibirsk</city>
        <zip>630091</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research facility ID ORG-000841</name>
      <address>
        <city>Odintsovo</city>
        <zip>143007</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site reference ID 89453</name>
      <address>
        <city>Rostov-on-Don</city>
        <zip>344010</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site reference ID 89418</name>
      <address>
        <city>Saratow</city>
        <zip>410012</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site reference ID 89456</name>
      <address>
        <city>St. Petersburg</city>
        <zip>198255</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site reference ID 89415</name>
      <address>
        <city>Ufa</city>
        <zip>450009</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site reference ID 89455</name>
      <address>
        <city>Volgograd</city>
        <zip>400134</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research facility ID ORG-000345</name>
      <address>
        <city>Donetsk</city>
        <zip>83045</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site reference ID 93715</name>
      <address>
        <city>Ivano-Frankivsk</city>
        <zip>76014</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site reference ID 93713</name>
      <address>
        <city>Kharkiv</city>
        <zip>61000</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site reference ID 93454</name>
      <address>
        <city>Kiev</city>
        <zip>04112</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site reference ID 93475</name>
      <address>
        <city>Mykolaiv</city>
        <zip>54001</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site reference ID 93714</name>
      <address>
        <city>Sevastopol</city>
        <zip>99011</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site reference ID 93474</name>
      <address>
        <city>Simferopol</city>
        <zip>95006</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site reference ID 95738</name>
      <address>
        <city>Zaporizhzhia</city>
        <zip>69032</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site reference ID 93455</name>
      <address>
        <city>Zaporizhzhia</city>
        <zip>69060</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Russian Federation</country>
    <country>Ukraine</country>
  </location_countries>
  <verification_date>February 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 28, 2012</study_first_submitted>
  <study_first_submitted_qc>December 28, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 3, 2013</study_first_posted>
  <results_first_submitted>February 12, 2015</results_first_submitted>
  <results_first_submitted_qc>February 12, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 27, 2015</results_first_posted>
  <last_update_submitted>February 12, 2015</last_update_submitted>
  <last_update_submitted_qc>February 12, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 27, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Meniere Disease</keyword>
  <keyword>Betahistine Dihydrochloride</keyword>
  <keyword>Vertigo</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vertigo</mesh_term>
    <mesh_term>Dizziness</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Betahistine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Vestibular Vertigo</title>
          <description>Patients with vestibular vertigo of known or unknown origin, and for whom the physician has decided to prescribe betahistine dihydrochloride at dose 48 mg/day in accordance with locally approved label</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>30 Days Treatment Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="309"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="305"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>60 Days Treatment Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="305"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="305"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Follow-up Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="305"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="305"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Patients with vestibular vertigo of known or unknown origin, and for whom the physician has decided to prescribe 48 mg of Betaserc® in accordance with locally approved label.</population>
      <group_list>
        <group group_id="B1">
          <title>Vestibular Vertigo</title>
          <description>Patients with vestibular vertigo of known or unknown origin, and for whom the physician has decided to prescribe betahistine dihydrochloride at dose 48 mg/day in accordance with locally approved label</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="309"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53.5" spread="15.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="220"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Ukraine</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="102"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Russian Federation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="207"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Scale for Vestibular Vertigo Severity Level and Clinical Response Evaluation (SVVSLCRE)</title>
        <description>Number of patients with clinical response on treatment determined with SVVSLCRE</description>
        <time_frame>Up to 2 months</time_frame>
        <population>60 days treatment group</population>
        <group_list>
          <group group_id="O1">
            <title>Vestibular Vertigo</title>
            <description>Patients with vestibular vertigo of known or unknown origin, and for whom the physician has decided to prescribe betahistine dihydrochloride at dose 48 mg/day in accordance with locally approved label</description>
          </group>
        </group_list>
        <measure>
          <title>Scale for Vestibular Vertigo Severity Level and Clinical Response Evaluation (SVVSLCRE)</title>
          <description>Number of patients with clinical response on treatment determined with SVVSLCRE</description>
          <population>60 days treatment group</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="305"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>excellent</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>very good</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>good</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="104"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>no change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>worsening</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change of the Patient’s Clinical Conditions of Vestibular Vertigo From Baseline to the End of Observational Treatment Period</title>
        <description>determined with the Scale for Vestibular Vertigo Severity Level and Clinical Response Evaluation (SVVSLCRE)</description>
        <time_frame>From Day 0 to 2 months</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change of Vestibular Vertigo Attacks Frequency From Baseline to the End of Observational Treatment Period</title>
        <time_frame>From Day 0 to 2 months</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change of Vestibular Vertigo Attacks Frequency From the End of Observational Treatment Period to the End of Follow-up Period</title>
        <time_frame>From 2 months to 4 months</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Clinical Response Assessed by Physician</title>
        <description>determined with a four-point-scale, where 4 = excellent, 3 = good, 2 = fair, and 1 = poor.</description>
        <time_frame>up to 2 months</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Clinical Response Assessed by Patient</title>
        <description>determined with a four-point-scale, where 4 = excellent, 3 = good, 2 = fair, and 1 = poor.</description>
        <time_frame>up to 2 months</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Response as Improvement of Vertigo Associated Symptoms Evaluated by Physician</title>
        <description>vertigo associated symptoms: tinnitus, hearing loss, nausea, vomiting, faintness and headache; determined with a four-point-scale, where 4 = excellent, 3 = good, 2 = fair, and 1 = poor.</description>
        <time_frame>up to 2 months</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Response as Improvement of Vertigo Associated Symptoms Evaluated by Patient</title>
        <description>vertigo associated symptoms: tinnitus, hearing loss, nausea, vomiting, faintness and headache; determined with a four-point-scale, where 4 = excellent, 3 = good, 2 = fair, and 1 = poor.</description>
        <time_frame>up to 2 months</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>Serious adverse events will be reported to Abbott from the time the physician obtains the patient's authorization to use and disclose information (or the patient's informed consent) until 30 days following the intake of the last dose of physician-prescribed treatment.</desc>
      <group_list>
        <group group_id="E1">
          <title>Vestibular Vertigo</title>
          <description>Patients with vestibular vertigo of known or unknown origin, and for whom the physician has decided to prescribe betahistine dihydrochloride at dose 48 mg/day in accordance with locally approved label</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="309"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="309"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Investigator shall not publish /present the results without Abbott’s prior written consent. In the event that applicable law permits Investigator to publish or present results without Abbott’s prior written consent, Investigator shall provide Abbott with a complete copy of such publication or presentation at least 60 days prior to submission for publication or presentation and Investigator shall reasonably consider all comments which Abbott may provide regarding such publication or presentation.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>4 patients had a treatment exposure of 30 days. No subgroup analyses were performed as the majority of patients had 60 days treatment with Betaserc®.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Associate Director Clinical Services</name_or_title>
      <organization>Abbott</organization>
      <email>taco.baardman@abbott.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

